Should work done on coronaviruses in Wuhan, China, be considered “gain-of-function” research? Opinions differ.
The U.S.’s top infectious disease specialist describes a new Biden administration program to develop and test antivirals—and what he’s most worried about as the nation reopens
Developing pills that block the novel coronavirus has been challenging. A new Biden administration program aims to boost the effort
With the risks of drug development prohibitive, repurposed or repositioned medicines appear the best hope against long-COVID, a condition that still raises many unanswered questions.
Genomic sequencing efforts are limited in developing countries, but scientists are mobilizing to help
More than a year into the SARS-CoV-2 pandemic, some scientists say the possibility of a lab leak never got a fair look.